Use of certain antiviral drugs during pregnancy not linked to birth defects
August 25th, 2010 - 4:36 pm ICT by ANIWashington, Aug 25 (ANI): Use of certain antiviral drugs during pregnancy not linked to higher risk of major birth defects, according to a new study.
An analysis of data from Denmark found no associated increased risk of major birth defects for mothers who were exposed during the first trimester of pregnancy to the antiviral drugs acyclovir, valacyclovir, and famciclovir, often used to treat herpes simplex and herpes zoster infections.
The prevalence of herpes simplex is high, and more than 1 percent of susceptible women acquire herpes simplex during the first trimester of pregnancy, with antiviral treatment indicated for a significant number of women in pregnancy.
“Although the safety of acyclovir, valacyclovir, and famciclovir in general has been well established, data on the use of these antivirals in early pregnancy are limited,” the authors said.
Bjorn Pasternak, and Anders Hviid, M.Sc., Dr.Med.Sci., of Statens Serum Institut, Copenhagen, Denmark, conducted a registry-based study to assess associations between acyclovir, valacyclovir, and famciclovir use in the first trimester of pregnancy and major birth defects.
The study included 837,795 live-born infants in Denmark from January 1996 to September 2008. Participants had no diagnoses of chromosomal aberrations, genetic syndromes, birth defect syndromes with known causes, or congenital viral infections.
Nationwide registries were used to ascertain individual-level information on dispensed antiviral drugs, birth defect diagnoses and potential confounders (factors that can influence outcomes).
Among 1,804 pregnancies exposed to acyclovir, valacyclovir, or famciclovir at any time in the first trimester, 40 infants (2.2 percent) had a diagnosis of a major birth defect, compared with 19,920 of 835,991 infants (2.4 percent) among the unexposed pregnancies.
Adjusting for several variables, acyclovir, valacyclovir, or famciclovir exposure at any time in the first trimester was not associated with increased risk of major birth defects.
First-trimester use of acyclovir, the most commonly prescribed antiviral, was not associated with major birth defects (32 cases among 1,561 exposed [2.0 percent] vs. 2.4 percent in the unexposed).
Neither valacyclovir (7 of 229 infants [3.1 percent]) nor famciclovir (1 of 26 infants [3.8 percent]) were associated with major birth defects, although use of famciclovir was uncommon.
Additional analyses revealed no associations between antiviral drug exposure and 13 different subgroups of birth defects, but the number of exposed cases in each subgroup was small.
The study appears in the August 25 issue of JAMA. (ANI)
- Study: No birth defect risk seen with pregnancy malaria drug - Feb 23, 2011
- Study: Smoking during pregnancy may cause heart problems in babies - Mar 08, 2011
- Smoking early in pregnancy linked to risk of heart defects in infants - Mar 01, 2011
- Scientists unravel herpes virus protein structure - Jul 27, 2010
- Smoking during pregnancy may cause heart defects in infants - Mar 01, 2011
- More kids being born with flattened heads - Apr 06, 2011
- Psychotropic drugs can cause birth defects - Jun 26, 2010
- Prenatal smoking exposure may lead to psychiatric problems - May 04, 2010
- Study associates herpes to Alzheimer's disease - Apr 05, 2011
- Pregnant diabetics more prone to birth defect: Study - Apr 05, 2012
- Breast cancer among pregnant women on rise - Dec 13, 2010
- Mums-to-be on prescription drugs likely to have kids with congenital defects - Nov 18, 2009
- Psychotropic drugs can cause birth defects - Jun 26, 2010
- Pregnancy stress can affect baby's iron status: Study - Apr 30, 2012
- Treatment of pregnant breast cancer patients shouldn't be delayed - Dec 13, 2010
Tags: antiviral drugs, antiviral treatment, antivirals, birth defect, birth defects, bjorn, chromosomal aberrations, congenital viral infections, copenhagen denmark, dr med, early pregnancy, famciclovir, first trimester of pregnancy, herpes, med sci, pasternak, statens serum institut, susceptible women, trimester of pregnancy, valacyclovir